Bacteria	Ceftazidime/cefepime*	Ceftriaxone/cefotaxime	Fluoroquinolones†	Aminoglycosides‡	Ertapenem	Imipenem/meropenem	Pip-tazo/ticar-clav	Tige-cycline
Acinetobacter species	++	+/++	+++	+++	–	+++	+++	+++
Citrobacter freundii	++/+++	++/+++	++++	++++	++++	++++	+++/++++	NA
Enterobacter aerogenes	++/+++	++/+++	++++	++++	++++	++++	+++/++++	+++
Enterobacter cloacae	++/+++	++/+++	++++	++/+++	++++	++++	++	+++
Escherichia coli	++++	++++	+++	++++	++++	++++	++++	++++
E coli (ESBL)	–	–	++	+++	++++	++++	–/+	+++
Klebsiella pneumoniae	++++	++++	++++	++++	++++	++++	++++	++++
K pneumoniae (ESBL)	–	–	+++	++++	++++	++++	–/+	+++
K pneumoniae (ampC)	++	++	++++	++++	+++	++++	–/+	++++
Morganella morganii	++/+++	++/+++	++++	+++/++++	++++	++++	++++	NA
Proteus mirabilis	++++	++++	+++/++++	++++	++++	++++	++++	+
Proteus vulgaris	++	++	++++	+++/++++	++++	++++	++++	NA
Providencia rettgeri	++/+++	+++	+++	+	+++	++++	++++	NA
Providencia stuartii	++/+++	+++	+++	++	+++	++++	++++	NA
Pseudomonas aeruginosa	+++	+	+++	+++	–	+++	+++	–/+
Serratia marcescens	+++	+++	+++	++	++++	++++	++++	+++

^*Cefepime has activity against ampC-producing organisms;

^†Includes ciprofloxacin, levofloxacin, moxifloxacin (moxifloxacin has only moderate activity against Pseudomonas aeruginosa);

^‡Includes gentamicin, netilmicin, tobramycin, amikacin. – Poor activity; + Limited activity and/or resistance ≥15%; ++ Moderate to good activity and/or resistance 10% to 14%; +++ Very good activity and/or resistance 5% to 9%; ++++ Excellent activity and/or resistance <5%; ESBL Extended-spectrum beta-lactamase; NA Not available; Pip-tazo Pipercillin-tazobactam; Ticar-clav Ticarcillin-clavulanate. Data adapted from references 216,248–255